Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

495 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Detection of karyotypic aberrations in acute myeloblastic leukaemia: a prospective comparison between PCR/FISH and standard cytogenetics in 140 patients with de novo AML.
Krauter J, Peter W, Pascheberg U, Heinze B, Bergmann L, Hoelzer D, Lübbert M, Schlimok G, Arnold R, Kirchner H, Port M, Ganser A, Heil G. Krauter J, et al. Among authors: bergmann l. Br J Haematol. 1998 Oct;103(1):72-8. doi: 10.1046/j.1365-2141.1998.00926.x. Br J Haematol. 1998. PMID: 9792292 Free article.
Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML).
Ganser A, Heil G, Seipelt G, Hofmann W, Fischer JT, Langer W, Brockhaus W, Kolbe K, Ittel TH, Brack N, Fuhr HG, Knuth P, Höffken K, Bergmann L, Hoelzer D. Ganser A, et al. Among authors: bergmann l. Ann Hematol. 2000 Jan;79(1):30-5. doi: 10.1007/s002770050005. Ann Hematol. 2000. PMID: 10663618 Clinical Trial.
Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK, Heil G, Zander C, Wiebe S, Ottmann OG, Bergmann L, Hoeffken K, Fischer JT, Knuth A, Kolbe K, Schmoll HJ, Langer W, Westerhausen M, Koelbel CB, Hoelzer D, Ganser A. Hofmann WK, et al. Among authors: bergmann l. Ann Hematol. 2004 Aug;83(8):498-503. doi: 10.1007/s00277-004-0889-0. Epub 2004 May 20. Ann Hematol. 2004. PMID: 15156346 Clinical Trial.
Aggressive chemotherapy combined with G-CSF and maintenance therapy with interleukin-2 for patients with advanced myelodysplastic syndrome, subacute or secondary acute myeloid leukemia--initial results.
Ganser A, Heil G, Kolbe K, Maschmeyer G, Fischer JT, Bergmann L, Mitrou PS, Heit W, Heimpel H, Huber C, et al. Ganser A, et al. Among authors: bergmann l. Ann Hematol. 1993 Mar;66(3):123-5. doi: 10.1007/BF01697620. Ann Hematol. 1993. PMID: 7682447 Clinical Trial.
Prospective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therapy in adult patients with acute lymphoblastic leukemia.
Hofmann WK, Seipelt G, Langenhan S, Reutzel R, Schott D, Schoeffski O, Illiger HJ, Hartmann F, Balleisen L, Franke A, Fiedler F, Huber C, Rasche H, Bergmann L, Ganser A, Pott C, Pasold R, Rudolph C, Ottmann OG, Gökbuget N, Hoelzer D. Hofmann WK, et al. Among authors: bergmann l. Ann Hematol. 2002 Oct;81(10):570-4. doi: 10.1007/s00277-002-0542-8. Epub 2002 Oct 17. Ann Hematol. 2002. PMID: 12424538 Clinical Trial.
495 results